Urinary exosomal miRNA signature in type II diabetic nephropathy patients

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Delić, Denis ^a   Eisele, Claudia ^a   Schmid, Ramona ^a   Baum, Patrick ^a   Wiech, Franziska ^a   Gerl, Martin ^a   Zimdahl, Heike ^a   Pullen, Steven S ^b   Urquhart, Richard ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1227 5P; MICRORNA 1234 5P; MICRORNA 1915 5P; MICRORNA 2861; MICRORNA 30D 5P; MICRORNA 30E 5P; MICRORNA 320C; MICRORNA 371B 5P; MICRORNA 4270; MICRORNA 4739; MICRORNA 4778 5P; MICRORNA 572; MICRORNA 6068; MICRORNA 6126; MICRORNA 6133; MICRORNA 638; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; EXOSOME; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; RNA ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; AGED; ALBUMINURIA; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; URINE; YOUNG ADULT;

ADULT; AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EXOSOMES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84960925899     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150154     Document Type: Article

References (72)

1. Chan G, Tang SC. Current practices in the management of diabetic nephropathy. J R Coll Physicians Edinb. 2013; 43: 330-332. doi: 10.4997/JRCPE.2013.413 PMID: 24350318
2. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2002; 31: 462-465.
3. Lambers Heerspink HJ, de Zeeuw D. Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31: 458-461. doi: 10.1159/ 000292501 PMID: 20413960
4. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31: 469-470. doi: 10.1159/000292500 PMID: 20413964
5. Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol. 2006; 1: 874-884. PMID: 17699300
6. Fried LF, Lewis J. Rebuttal of the Pro View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD. Clin J Am Soc Nephrol. 2015; 10: 1095-1098. doi: 10.2215/CJN.01610215 PMID: 25887072
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297. PMID: 14744438
8. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466: 835-840. doi: 10.1038/nature09267 PMID: 20703300
9. Wing MR, Ramezani A, Gill HS, Devaney JM, Raj DS. Epigenetics of progression of chronic kidney disease: fact or fantasy? Semin Nephrol. 2013; 33: 363-374. doi: 10.1016/j.semnephrol.2013.05.008 PMID: 24011578
10. Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 2008; 18: 404-411. doi: 10.1101/gr.6587008 PMID: 18230805
11. Chung AC, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol. 2010; 21: 1317-1325. doi: 10.1681/ASN.2010020134 PMID: 20488955
12. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007; 104: 3432-3437. PMID: 17360662
13. Harvey SJ, Jarad G, Cunningham J, Goldberg S, Schermer B, Harfe BD, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol. 2008; 19: 2150-2158. doi: 10.1681/ASN.2008020233 PMID: 18776121
14. Wu J, Zheng C, Fan Y, Zeng C, Chen Z, Qin W, et al. Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids. J Am Soc Nephrol. 2014; 25: 92-104. doi: 10.1681/ ASN.2012111101 PMID: 24029422
15. Shi S, Yu L, Zhang T, Qi H, Xavier S, Ju W, et al. Smad2-dependent downregulation of miR-30 is required for TGF-β-induced apoptosis in podocytes. PLoS One. 2013; 8: e75572. doi: 10.1371/journal. pone.0075572 PMID: 24086574
16. Lai JY, Luo J, O'Connor C, Jing X, Nair V, Ju W, et al. MicroRNA-21 in glomerular injury. J Am Soc Nephrol. 2015; 26: 805-816. doi: 10.1681/ASN.2013121274 PMID: 25145934
17. Glowacki F, Savary G, Gnemmi V, Buob D, Van der Hauwaert C, Lo-Guidice JM, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One. 2013; 8: e58014. doi: 10.1371/ journal.pone.0058014 PMID: 23469132
18. McClelland AD, Herman-Edelstein M, Komers R, Jha JC, Winbanks CE. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond). 2015; 129: 1237-1249.
19. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014; 63: 2120-2131. doi: 10.2337/db13-1029 PMID: 24574044
20. Lorenzen JM, Thum T. Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol. 2012; 7: 1528-1533. doi: 10.2215/CJN.01170212 PMID: 22580786
21. Yang Y, Xiao L, Li J, Kanwar YS, Liu F, Sun L. Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses. 2013; 81: 274-248. doi: 10.1016/j. mehy.2013.04.031 PMID: 23683774
22. Argyropoulos C, Wang K, McClarty S, Huang D, Bernardo J, Ellis D, et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One. 2013; 8: e54662. doi: 10.1371/journal.pone.0054662 PMID: 23358711
23. Argyropoulos C, Wang K, Bernardo J, Ellis D, Orchard T, Galas D, et al. Urinary MicroRNA Profiling Predicts the Development of Microalbuminuria in Patients with Type 1 Diabetes. J Clin Med. 2015; 4: 1498-1517. doi: 10.3390/jcm4071498 PMID: 26239688
24. van Balkom BW, Pisitkun T, Verhaar MC, Knepper MA. Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int. 2011; 80: 1138-1145. doi: 10.1038/ki.2011.292 PMID: 21881557
25. Miranda KC, Bond DT, McKee M, Skog J, Paunescu TG, Da Silva N, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 2010; 78:191-199. doi: 10.1038/ki.2010.106 PMID: 20428099
26. Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, Gleadle JM. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant. 2011; 26: 3794-3802. doi: 10.1093/ndt/ gfr485 PMID: 21891774
27. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29: 341-345. doi: 10.1038/ nbt.1807 PMID: 21423189
28. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12: 347-357. doi: 10.1038/nrd3978 PMID: 23584393
29. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004; 101: 13368-13373. PMID: 15326289
30. Erdbrügger U, Le TH (2015) Extracellular Vesicles in Renal Diseases: More than Novel Biomarkers? J Am Soc Nephrol. 2016; 27: 12-26. doi: 10.1681/ASN.2015010074 PMID: 26251351
31. Ramezani A, Devaney JM, Cohen S, Wing MR, Scott R, Knoblach S, et al. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study. Eur J Clin Invest. 2015; 45: 394-404. doi: 10.1111/eci.12420 PMID: 25682967
32. Barutta F, Tricarico M, Corbelli A, Annaratone L, Pinach S, Grimaldi S, et al. Urinary exosomal micro-RNAs in incipient diabetic nephropathy. PLoS One. 2013; 8: e73798. doi: 10.1371/journal.pone. 0073798 PMID: 24223694
33. Solé C, Cortés-Hernández J, Felip ML, Vidal M, Ordi-Ros J. miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. Nephrol Dial Transplant. 2015; 30: 1488-1496. doi: 10.1093/ ndt/gfv128 PMID: 26040904
34. Alvarez ML, Khosroheidari M, Kanchi Ravi R, DiStefano JK. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012; 82: 1024-1032. doi: 10.1038/ki.2012.256 PMID: 22785172
35. Alvarez ML. Isolation of urinary exosomes for RNA biomarker discovery using a simple, fast, and highly scalable method. Methods Mol Biol. 2014; 1182: 145-170. doi: 10.1007/978-1-4939-1062-5-13 PMID: 25055908
36. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014; 42: D68-73. doi: 10.1093/nar/gkt1181 PMID: 24275495
37. R Development Core Team: R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2003. Available: http://www.Rproject.org
38. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biology. 2004; 5: R80. PMID: 15461798
39. López-Romero P. Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library. BMC Genomics. 2011; 12: 64. doi: 10.1186/1471-2164-12-64 PMID: 21269452
40. Hampel FR. The Breakdown Points of the Mean Combined with Some Rejection Rules. Technometrics. 1985; 27: 95-107.
41. Smyth GK. Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer, New York. 2005; 397-420.
42. Benjamini Y. and Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B. 1995; 57: 289-300.
43. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001; 125: 279-284. PMID: 11682119
44. Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2014; 64: 5245-5250.
45. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-408. PMID: 11846609
46. Louafi F, Martinez-Nunez RT, Sanchez-Elsner T. MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}. J Biol Chem. 2010; 285: 41328-41336. doi: 10.1074/jbc.M110.146852 PMID: 21036908
47. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci U S A. 2010; 107: 3111-3116. doi: 10.1073/pnas.0910667107 PMID: 20133617
48. Sallustio F, Costantino V, Cox SN, Loverre A, Divella C, Rizzi M, et al. Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvesicle-shuttled decorin. Kidney Int. 2013; 83: 392-403. doi: 10.1038/ki.2012.413 PMID: 23325086
49. Sallustio F, Serino G, Costantino V, Curci C, Cox SN, De Palma G, et al. miR-1915 and miR-1225-5p regulate the expression of CD133, PAX2 and TLR2 in adult renal progenitor cells. PLoS One. 2013; 8: e68296. doi: 10.1371/journal.pone.0068296 PMID: 23861881
50. Wang C, Hu J, Lu M, Gu H, Zhou X, Chen X, et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep. 2015; 5: 7610. doi: 10.1038/srep07610 PMID: 25556603
51. Meng XM, Huang XR, Xiao J, Chen HY, Zhong X, Chung AC, et al. Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro. J Pathol. 2012; 227: 175-188. doi: 10.1002/path. 3976 PMID: 22190171
52. Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens. 2012; 21: 410-416. doi: 10.1097/MNH.0b013e328354e559 PMID: 22622653
53. Chung AC, Yu X, Lan HY. MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis. 2013; 6: 169-179. doi: 10.2147/IJNRD.S37885 PMID: 24109192
54. Ramdas V, McBride M, Denby L, Baker AH. Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29. Am J Pathol. 2013; 183: 1885-1896. doi: 10.1016/j.ajpath.2013.08.027 PMID: 24103556
55. Lv LL, Cao YH, Ni HF, Xu M, Liu D, Liu H, et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol. 2013; 305: F1220-1227. doi: 10.1152/ ajprenal.00148.2013 PMID: 23946286
56. Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci (Lond). 2010; 119: 395-405.
57. Macconi D, Tomasoni S, Romagnani P, Trionfini P, Sangalli F, Mazzinghi B, et al. MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol. 2012; 23: 1496-1505. doi: 10.1681/ASN.2011121144 PMID: 22822076
58. Okada H. Angiotensin converting enzyme inhibitor-modulated microRNAs targeting renal fibrosis. J Am Soc Nephrol. 2012; 23: 1441-1443. doi: 10.1681/ASN.2012070692 PMID: 22878962
59. Nassirpour R, Mathur S, Gosink MM, Li Y, Shoieb AM, Wood J, et al. Identification of tubular injury microRNA biomarkers in urine: comparison of next-generation sequencing and qPCR-based profiling platforms. BMC Genomics. 2014; 15: 485. doi: 10.1186/1471-2164-15-485 PMID: 24942259
60. Ukai T, Sato M, Akutsu H, Umezawa A, Mochida J. MicroRNA-199a-3p, microRNA-193b, and micro-RNA-320c are correlated to aging and regulate human cartilage metabolism. J Orthop Res. 2012; 30: 1915-1922. doi: 10.1002/jor.22157 PMID: 22674437
61. Hamam D, Ali D, Vishnubalaji R, Hamam R, Al-Nbaheen M, Chen L, et al. microRNA-320/RUNX2 axis regulates adipocytic differentiation of human mesenchymal (skeletal) stem cells. Cell Death Dis. 2014; 5: e1499. doi: 10.1038/cddis.2014.462 PMID: 25356868
62. Wang X, Wu J, Lin Y, Zhu Y, Xu X, Xu X, et al. MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6. J Exp Clin Cancer Res. 2013; 33: 69.
63. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk - database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform. 2011; 44: 839-847. doi: 10.1016/j.jbi. 2011.05.002 PMID: 21605702
64. Yan JD, Yang S, Zhang J, Zhu TH. BMP6 reverses TGF-beta1-induced changes in HK-2 cells: implications for the treatment of renal fibrosis. Acta Pharmacol Sin. 2009; 30: 994-1000. doi: 10.1038/aps. 2009.56 PMID: 19543302
65. Daniel C, Wiede J, Krutzsch HC, Ribeiro SM, Roberts DD, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int. 2004; 65: 459-468. PMID: 14717916
66. Ahamed J, Janczak CA, Wittkowski KM, Coller BS. In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring-and shear-dependent activation of platelet-derived TGF-beta1. PLoS One. 2009; 4: e6608. doi: 10.1371/journal.pone.0006608 PMID: 19672301
67. Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia. 2005; 48: 2650-2660. PMID: 16270194
68. Hohenstein B, Daniel C, Hausknecht B, Boehmer K, Riess R, Amann KU, et al. Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant. 2008; 23: 3880-3887. doi: 10.1093/ndt/gfn399 PMID: 18676351
69. Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol. 2011; 178: 2573-2586. doi: 10.1016/j.ajpath.2011.02.039 PMID: 21641382
70. Frolova EG, Sopko N, Blech L, Popovic ZB, Li J, Vasanji A, et al. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J. 2012; 26: 2363-2373. doi: 10.1096/fj.11-190728 PMID: 22362893
71. Wang X, Huang W, Liu G, Cai W, Millard RW, Wang Y, et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol. 2014; 74: 139-150. doi: 10.1016/j.yjmcc.2014.05.001 PMID: 24825548
72. Shantikumar S, Angelini GD, Emanueli C. Diabetes, microRNAs and exosomes: Les liaisons dangereuses. J Mol Cell Cardiol. 2014; 74:196-198. doi: 10.1016/j.yjmcc.2014.05.014 PMID: 24874423